Public Employees Retirement System of Ohio Makes New Investment in Repligen Corporation $RGEN

Public Employees Retirement System of Ohio purchased a new stake in shares of Repligen Corporation (NASDAQ:RGEN) in the second quarter, HoldingsChannel reports. The institutional investor purchased 55,503 shares of the biotechnology company’s stock, valued at approximately $7,573,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of RGEN. Measured Wealth Private Client Group LLC acquired a new stake in shares of Repligen in the third quarter valued at $29,000. Los Angeles Capital Management LLC bought a new stake in Repligen in the fourth quarter worth about $36,000. Northwestern Mutual Wealth Management Co. bought a new stake in Repligen in the second quarter worth about $52,000. Farther Finance Advisors LLC lifted its holdings in Repligen by 61.8% in the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 128 shares during the last quarter. Finally, Itau Unibanco Holding S.A. boosted its position in shares of Repligen by 38.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 104 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling

In other Repligen news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares of the company’s stock, valued at $2,807,055. The trade was a 3.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.60% of the company’s stock.

Wall Street Analysts Forecast Growth

RGEN has been the topic of a number of research reports. JPMorgan Chase & Co. boosted their target price on shares of Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Jefferies Financial Group reiterated a “hold” rating and set a $142.00 price objective on shares of Repligen in a research report on Tuesday, May 5th. Citigroup raised Repligen to a “buy” rating in a research note on Tuesday, July 7th. Weiss Ratings raised Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, August 13th. Finally, Zacks Research upgraded Repligen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Repligen currently has a consensus rating of “Buy” and a consensus price target of $166.43.

Repligen Trading Down 6.1%

Repligen stock opened at $170.02 on Wednesday. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $188.73. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The firm has a market capitalization of $9.60 billion, a price-to-earnings ratio of 232.90, a P/E/G ratio of 3.30 and a beta of 1.04. The company has a 50 day moving average price of $153.95 and a 200 day moving average price of $133.50.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business had revenue of $204.13 million during the quarter, compared to analysts’ expectations of $201.59 million. During the same quarter last year, the firm posted $0.26 earnings per share. Repligen’s revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Research analysts forecast that Repligen Corporation will post 2.06 EPS for the current year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.